A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection or Placebo in Combination with Chemotherapy Carboplatin/Cisplatin-Etoposide and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer LS-SCLC

Brief Summary

Type:
Lung Cancers

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT05353257

Study #:
STUDY00149777

Start Date:
Feb 15, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05353257

View Complete Trial Details & Eligibility at ClinicalTrials.gov